Home     Font Size: 1  2  3    Send to a Friend       search

2007 News Archive

Research Uncovers Molecular Function of Endosialin Target of MORAb-004, Anti-Angiogenic Antibody Being Evaluated for Cancer, Neovascular Disease

November 20, 2007

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.com Bryan Evans Reverb—DBC 215-957-0300...

+ Read the Article

Morphotek Receives U.S. Patent Regarding Methods for Generating Genetically Altered Antibodies with Enhanced Affinity and Antibodies Produced by them

November 19, 2007

Contact: Philip M. Sass Morphotek, Inc. 610-423-6100 info@morphotek.com Bryan Evans Reverb—DBC 215-957-0300...

+ Read the Article

Morphotek Receives $2.7M in Funding from the National Institute of Allergy and Infectious Diseases to Develop Therapeutic Antibodies against Biowarfare Agents

October 4, 2007

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.comBryan Evans Reverb—DBC 215-957-0300 ...

+ Read the Article

Morphotek Receives $2.3M in Funding from the U.S. Department of Defense to Develop Therapeutic Antibodies Against Biowarfare Agents

September 18, 2007

Contact: Nicholas Nicolaides Morphotek, Inc. 610-423-6100 info@morphotek.comBryan Evans Reverb—DBC 215-957-0300 ...

+ Read the Article

Morphotek CEO Named Ernst & Young Entrepreneur Of The Year® 2007 Award Winner in Greater Philadelphia Region

June 27, 2007

For Immediate Release Morphotek CEO Named Ernst & Young Entrepreneur Of The Year® 2007 Award Winner in...

+ Read the Article

Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO Annual Meeting

May 31, 2007

FOR IMMEDIATE RELEASE Contact: Judee Shuler Eisai Inc. During ASCO: 908-337-2540 Office: 201-746-2241 ...

+ Read the Article

Morphotek Receives Protocol Approval from German Regulatory Authority for Phase II Trial Site Selections in Heidelberg and Frankfurt

May 23, 2007

Company Embarks in Global Study of MORAb-003 to Treat Ovarian Cancer EXTON, Pa.--(BUSINESS WIRE)--Morphotek, Inc., a U.S. subsidiary of...

+ Read the Article

Morphotek Signs Development and Clinical Supply Agreement with CMC Biopharmaceuticals A/S for Therapeutic Antibody to Treat Melanoma

May 21, 2007

EXTON, Pa.--(BUSINESS WIRE)--Morphotek, Inc., a U.S. subsidiary of Eisai Co., Ltd., announced today that the company has entered into agreement...

+ Read the Article

Eisai Announces Completion of Acquisition of Morphotek

April 17, 2007

FOR IMMEDIATE RELEASE Contacts: Corporate Communications Department Eisai Co., Ltd. 011-81-3-3817-5120 Cathy Pollini Eisai Inc....

+ Read the Article

Eisai To Acquire Morphotek

March 21, 2007

Eisai's Dramatic Leap towards Biologic Therapeutics Evidenced by the Acquisition TOKYO, Japan, WOODCLIFF...

+ Read the Article

Go to Page: 1 2

Results per page   10  25  50